Bio Job Blog : Bio Jobs : Biotechnology Jobs : Biopharmaceutical Jobs : Bioscience, Biotech Jobs : Bio Job Blog : Biocareer : Bio-Business Training, Biotechnology Training : Jobs in Biology : Internships in Biology : Internships in Biotechnology

The public hearing held by FDA last week in Washington DC to address social media and promotional advertising in the pharmaceutical seems to have altered the agency’s perspective on all things digital. Today, according to a press release, marked the agency’s completion of a coordinated week long international effort called the International Week of Action (IIWA) that was intended to curb illegal actions involving medical and pharmaceutical products.

During the effort, the FDA's Office of Criminal Investigations (OCI), in conjunction with the Center for Drug Evaluation and Research and the Office of Regulatory Affairs, Office of Enforcement, targeted 136 Web sites that appeared to be engaged in the illegal sale of unapproved or misbranded drugs to U.S. consumers. None of the Web sites are for pharmacies in the United States or Canada.

The agency issued 22 warning letters to the operators of these Web sites and notified Internet service providers and domain name registrars that the Web sites were selling products in violation of U.S. law. In many cases, because of these violations, Internet service providers and domain name registrars may have grounds to terminate the Web sites and suspend the use of domain names. Apparently, FDA has taken to sending warning letter en masse—it previously sent identical warning letters to 14 different pharmaceutical companies for improprieties associated with Google search ads.

Is there really a sea change taking place at FDA? Will a carefully and thoughtfully- crafted guidance document on the use of social media be next; now that the agency is no longer afraid to navigate the Internet? Only time will tell....hopefully sooner, rather than later!

Until next time...

Good Luck and Good Surfing!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Unlike many of my social media colleagues, I’m not attending the FDA public hearing taking place in Washington, D.C today (Friday the 13^th oh my). I wanted to attend and actually testify but I didn’t understand how the process works and blew my opportunity. However, I will be prepared for rounds 2 and 3 and beyond. I can assure you that this will not be the last public meeting organized by the agency to develop guidance for the use of social media in pharmaceutical marketing and advertising. 

The brouhaha over social media and its use in the life sciences industry is purportedly taking place because of the lack of regulatory guidance on the topic. While I agree that FDA needs to craft a reasonable regulatory policy for the use of social media for promotional purposes, the discussion taking place has little to do with the medium and everything to do with the fair balance of ads that are used to promote drug sales. For those of you who may not know, fair balance (in regulatory parlance) means that drug manufacturers are required to fully disclose in print, television, radio and internet ads the benefits as well as the side effects and risks associated with a specific product. Unfortunately, too often, drug makers tend to promote the therapeutic benefits of a drug but downplay its side effects and risks. This isn’t surprising because drug makers, like other for-profit companies, must sell as much product as possible to generate sufficient revenues to remain profitable.  And, as we all know, consumers and physicians are more likely to use or prescribe drugs that have therapeutic benefits without many side effects or risks.

Since the inception of direct-to-consumer advertising, FDA and drug makers have been playing a cat-and mouse-game with the fair balance issue. Most drug makers understand the “balance” that FDA requires for traditional promotional ads, but rather than abide by the rules, many choose to determine how far they can bend the rules before they appear on FDA’s radar. Therefore, it should come as no surprise that drug companies have adopted the same strategy when it comes to Internet advertising and search result ads. To be fair, FDA hasn’t crafted any definitive guidance on Internet advertising or search ad fair balance requirements. However, rather than apply what they have learned over the years about fair balance in print and television advertising, many drug makers chose to ignore fair balance requirements for Internet advertising simply because there are no written regulations or rules. To that end, 14 pharmaceutical and biotechnology companies recently received warning letters about their misuse of promotional drug ads that appeared with Google search results. FDA cited the lack of fair balance in the search ads as reasons for the warning letters. By issuing identical warning letters to 14 different drug companies, the agency was essentially saying “c’mon guys, who are you trying to kid—you ought to know better by now!”

Unfortunately, even when there are regulations, many companies spend hundreds of millions of dollars to look for deficiencies and loopholes that can be exploited to increase and improve drug sales. Therefore, I contend, that regardless of the social media guidance that FDA ultimately issues, drug and device manufacturers will continue to look for work arounds to regulations that they perceive hinder product sales.  

Social media is all about transparency, accessibility and communications between participants. The guidance that FDA issues about the use of social media in the life sciences industry will likely be circumspect and open to interpretation as it usually is. As one FDA legal expert explained to me, “FDA crafts the laws but it is up to the judiciary  to interpret how they ought to be applied.”

I suspect little will change until drug manufacturers realize that full disclosure and transparency, not half-truths and opaqueness, will ultimately lead to improved drug sales in the future.

Until next time...

Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

In today’s edition of the incisive EyeonFDA blog, Mark Senak, provides a historical perspective on events leading to the US Food and Drug Administration public hearing on the use of social media and medical promotion that will be held on Thursday and Friday, November 12 and 13, 2009. As Mark points out, registration for the meeting was closed because of an overwhelming response and the number of people who wanted to offer testimony on the topic. Many social media enthusiasts view the public hearing as something of a “game changer” that may influence the future direction of social media in the life sciences industry. But, as Mark, astutely points out, only four pharmaceutical companies and one or two trade organizations will be participating at the hearing. 

The lack of industry participation at the meeting is curious given that 14 companies received warning letters several months ago about their misuse of ad associated with the results obtain by Google search. Further, pharmaceutical companies have consistently and publicly stated that their aversion to social media is contingent upon the lack of FDA’s regulatory guidance for its use. By not actively participating in the public hearings later this week, many pharma companies have chosen to remain silent and will likely allow FDA to craft social media policies that guide the promotional activities of drug makers on its own. This begs the question: why would drug makers allow a federal regulatory agency to unilaterally dictate policy, when the policy will likely affect their bottom lines, i.e. sales and profits? The industry’s refusal to actively participate in these hearings is another example of the cat and mouse game that drug makers like to play with FDA. Put simply, drug makers expect and want FDA to commit (in writing) to certain policies and guidelines and once established, company regulators and lawyers are instructed to find loopholes and work-arounds. I liken the drug industry’s refusal to actively participate in the upcoming public hearings to the now infamous rope-ad-dope strategy Mohammed Ali used to knock out George Foreman in the now infamous Rumble in the Jungle in 1974. This is how wikipedia defines the rope-a-dope: “The rope-a-dope is performed by a boxer assuming a protected stance, in Ali's classic pose, lying against the ropes, and allowing his opponent to hit him, in the hope that the opponent will become tired and make mistakes which the boxer can exploit in a counterattack.” I hope that I am wrong about the drug industry’s strategy and motives.

Without active industry participation it isn’t clear how effective the FDA public hearing on social media will be. As Mark adroitly points out in today’s post, “The bulk of the other presentations are tertiary stakeholders perhaps sensing a vehicle for free self-promotion such as advertising and public relations firms and bloggers, but they aren't the real stakeholders in this issue.  The real stakeholders are those who are referred to in the meeting notice - the medical products industry.” I would also add the American public to the stakeholder list who also has considerable “skin in the game.”

Pharma’s active participation at many of the social media conferences that I recently attended indicates that something must be in it for pharma; otherwise they wouldn’t attend. There is no question that social media isn’t a passing fad and is now an integral part of the Web 2.0 experience. That said, for the first time in many years, drug makers have a unique opportunity to actively voice their ideas and concerns and collaboratively work with FDA to craft meaningful social media regulatory guidance. As many of us “outside observers” know, the agency doesn’t have all the answers and we would like to think that drug makers would extend a helping hand to avoid confusion and misunderstandings about the use of social media to promote their products and services. While only 4 companies are scheduled to speak at the hearings, I suspect that there will be many life science company representatives in attendance. Nevertheless, despite what may happen at this week’s hearings, I hope that, going forward, drug makers and device manufacturers will begin to view FDA as a partner rather than an adversary!

Until next time...

Good Luck and Good Job Hunting!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

For the past several weeks, the EyeonFDA blog has been reporting on the possible regulatory impact of Google’s Sidewiki on life sciences companies. For those of you who may not be familiar with Sidewiki  (released in late September) it is a new feature of the Google toolbar which can turn a static web 1.0 website into an interactive web 2.0 experience by allowing website visitors to leave comments behind.

When you use side-wiki, you have the ability to leave your comments and associate them with a website whether or not the website owner has enabled commenting.  Since the comments are maintained by Google, there is no direct relationship with the website.  Basically, anybody who visits a website that has Sidewiki enabled can say or comment on whatever they like and immortalize it (until Google removes it) for the entire world to see. Apparently, this doesn’t sit well with many website owners and Google purportedly recently release code to disable Sidewiki at websites that don’t want to support it. However, it isn’t clear how robust the anti-sidewiki code is!

While I haven’t formulated an opinion on Side Wiki yet (mostly because it isn’t that interesting to me), it does represent a regulatory dilemma for life sciences companies with marketed drugs and devices. According to today’s EyeonFDA post “If someone writes of an adverse event on a Sidewiki, or promotes an off-label use, it is now on the company's home page.  Is the company under a duty to monitor and correct such misinformation or if they do, do they incur liability for doing so?  It is a conundrum - and there is no insight apparent from the FDA on the matter.” Further, most life sciences companies have yet to craft a legal or regulatory policy for Sidewiki usage. 

EyeonFDA has been assiduously monitoring life sciences company websites for the appearance of Sidewiki. To date EyeonFDA has found it on the following company websites:

1. Abbott
2. Amgen
3. AstraZeneca
4. Bayer
5. Baxter
6. Bristol-Myers Squibb
7. GSK
8. Johnson & Johnson
9. Lilly
10. Novartis
11. Novo Nordisk
12. Pfizer
13. Roche
14. Sanofi-Aventis
15. Takeda

While Google would like everyone to believe that Sidewiki is taking the Internet by storm and spreading like the H1N1 virus, a show of hands at yesterdays e-Patient Connections 2009 meeting in Philly, which was attended by many computer geeks and social media enthusiasts, revealed that about4 out of about 150 had heard of it! Nevertheless, it is out there and life sciences companies would be well advised to formulate internal legal and regulatory guidelines despite the fact that FDA hasn’t issued any guidance on its use.

P.S. Shortly after I posted this, @pharmaguy alerted me to an article that appeared on the today's online PharmaExec.com entitled "SideWiki: What's Pharma To Do"?

Until next time...

Good Luck and Good Commenting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

e-Patients Connections 2009 (#epatcon) was held this past Monday and Tuesday at the Park Hyatt hotel in Philadelphia, PA. BioCrowd was one of several co-sponsors of the event. The theme of the conference, organized by Kevin Kruse a veteran medical communication and training expert, who now runs Kru Research, was to “reach, engage and educate empowered digital health consumers.” And, boy, did it deliver! While this was Kru Research’s first official conference, it was well organized, extremely interactive and the quality of the speakers was second to none! Topics that were featured included social media and the life sciences industry, technological advances in e-based healthcare delivery, the relationship between the news media and healthcare information and the continuing evolution of online and e-based healthcare communities.

Conference attendees included representatives from the life sciences industry, medical communications experts, advertising and marketing professionals and a multitude of social media enthusiasts and consultants who kept the Twitter screen humming throughout the meeting (a big shout out to the “troublemaking table”). And, surprisingly, there was a representative from the Division of Drug Marketing and Advertising and Communications (DDMAC) at the US Food and Drug Administration, who I believe, was one of the most sought after individuals at the meeting. CNN reporter Elizabeth Cohen who writes the Empowered Patient and racecar driver Charles Kimball, a type I diabetic and company spokesperson for Novo Nordisk also gave talks.

My favorite talks were those presented by online patient community organizers including Tricia Geoghegan of Ortho-McNeil-Janssen Pharmaceuticals who created the Facebook ADHD Allies community, Lisa Tate of WomenHeart and Robert Schumm of Bayer Consumer Care who created Facebook Strong@ Heart and Rachel Lewinson of the Juvenile Diabetes Research Organization and Susan Harrow Rago of Novo Nordisk who created Juvenation.org a website dedicated to those with Type I diabetes. These communities are outstanding examples of how partnerships between pharmaceutical companies and advocacy groups can help to better educate the public and heighten awareness about potentially life-altering diseases. Another example of a great online community and healthcare portal is Insomnia 123.com. This website was conceived and constructed by Christine Macadams and her partners’ one of whom is a practicing physician. Unlike the other online communities, which are sponsored and mainly supported by consumer healthcare division of large pharmaceutical companies, Insomnia 123.com was exclusively created by a group of concerned individuals who wanted to better educate and improve the lives of people with insomnia—a largely unreported and self-medicated condition.

On the technical side, the talks presented by Lee Segal of Klick, Kevin Durr of Avantera , Ian Kelly of Red Nucleus and Scott Ballenger of ListenLogic were illuminating and extremely informative. Some of the innovations taking place in digital media are exciting and almost overwhelming at times (even for a social media enthusiast like me). I think the company to watch is ListenLogic which uses semantic search engines to collect real time data and “chatter” on the web. This technology may provide a cost-effective solution to assuage the concerns of many life sciences companies that claim that collecting and analyzing overwhelming amounts of data is one of the main reasons why they are reluctant to entry the social media space.

Marc Monseau of Johnson and Johnson gave an illuminating talk on his experiences as a corporate blogger and Twitter user and described some of the challenges that had to be overcome before his company was able to break the “social media barrier.” Janice McCallum, an economist by training and a healthcare communications and media expert gave an informative talk about the growing role and impact of patient-generated healthcare content on patient awareness and education.

Finally, the novel and innovative Pecha Kucha sessions were outstanding and extremely well done! While all were expertly crafted, Dr. Val’s and Jonathan Richman’s Pecha Kucha were memorable. Dr. Val’s, which was extremely powerful and moving, was performed entirely in verse and Jonathan’s was—well, one of Jonathan’s always entertaining and informative presentations.

In summary, the “e-Patient Connections 2009” was a resounding success and in my opinion reached its goal to “reach engage and educate empowered digital health consumers.” That said, I can’t wait for “e-Patient Connections 2010” meeting!!!

Hat tip to @ellenhoenig and @eileenobrien for inviting me to my first tweetup (great fun) and finally meeting @janice McCallum, @christianeTrue, @stevewoodruff and Silja aka @whydotpharma! 

Until next time...

Good Luck and Good Job Hunting!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The answer to this question is not yet! However, the The Wall Street Journal recently reported that 64% of U.S. physicians are using smart phones (up 50% from two years ago) and increasingly are relying on them to find medical information, manage patients and transmitting clinical data. To that end, a post at the Medical Translation Insights blog discusses the changing role of smart phones in healthcare and the regulatory challenges they may face if classified as medical devices.

 When Cell Phones Become Medical Devices

The definition of "medical device" is shifting, quickly and dramatically.  The revised MDD now includes stand-alone software in the definition. In other words,if software has a medical purpose, it probably can/must be CE marked. And smart phones are quickly becoming the conduit of choice for collecting and researching, disseminating, and evaluating clinical data.

As Bob on Medical Device Software points out, its unique user interface, display, and broadband capabilities make the Apple iPhone a particularly attractive platform for medical applications. For example, the AirStrip OBSERVER suite of applications is custom-designed for the iPhone, makes some components available for download at the Apple App Store, and received FDA clearance for some modalities.

While most medical apps fall into the reference category, applications are getting more sophisticated and are taking advantage of the devices networking abilities. A trio of applications developed by researchers at the University of Utah aptly demonstrate these advances. Another factor is the appeal and widespread use of these devices. The Wall Street Journal reports [login required] today that 64% of U.S. physicians are using smart phones.

There are several big questions and unknowns hanging over these developments: First and foremost, there is the question of data security. As quoted in the same WSJ article, Deborah Peel of Patient Privacy Rights worries that "the vast majority of health information technology has not been designed to ensure that patients control access to that data and use of that data". So, paradoxically, the more ways that doctors can access patients' records, the more their confidentiality is threatened.

Second, what is the quality threshold for smart phone applications? Just because something is on the iPhone doesn't mean it's necessarily a quality application

Regulators around the world are bound to tackle these questions. FDA, for instance, is already looking at this issue and sooner or later will regulate certain phones. It's certainly not the end of the world to be classified as a medical device, but verification and validation of these applications won't be easy.

 As these applications get developed and become part of a networked medical device, language will also become an issue again. Translation service providers will need to become familiar with smart phone development and localization issues and support consistently translated content across multiple platforms and media.

Until next time...

Good Luck and Good Job Hunting

ForeignExchange Translations provides specialized language services to pharmaceutical and medical device companies

• Email This
• Print
• Comments
• Trackbacks
• Share Link

I came across a recent post on Adage.com entitled “Pharma Drops Search Advertising After FDA Warning” that revealed that paid search ads by pharmaceutical companies dropped a 84% between March 26 of this year and the end of June. As you may recall, March 26 was when 14 companies received warning letters from the US Food and Drug Administration (FDA) indicating that they had violated marketing guidelines for search ad advertising. The letters stated that sponsored-link advertisements for specific drugs were misleading due to the exclusion of risk information associated with the use of the drug -- even though the regulatory agency's guidelines are for print and broadcast, not online or social media. Pharma companies that believed they were in compliance with the unwritten "one-click rule"— taking the consumer from the ad to a site that offered fair balance and the risk information by clicking on the ad. What? Did I read that correctly; the words “unwritten and FDA” in the same sentence? This is very surprising since anybody who has worked with the agency is well aware of the “if it isn’t written it didn’t happen” principle. But I digress....

The post went on to say that pharmaceutical companies are “fearful of running afoul” of the agency again. Say what? The words “pharma and fearful” used in the same sentence? The point that I am trying to make is that pharma chose to keep things vague about web-based advertising to see how far they can push the envelope with FDA instead of taking the proverbial “bull by the horns” and directly asking FDA for guidance on web 2.0 technologies and their uses. Wouldn’t it be in everyone’s best interest if companies took a more active role to help craft new rules on the use of new media technologies rather then rely on and wait for FDA to do it for them? While the old “cat and mouse” game worked for old media, it is no longer tenable when it comes to Web 2.0 and related technologies.

The FDA is holding public hearings next month to begin the process of establishing internet advertising guidelines and the use of social media in the life science industry. This offers drug and devices companies an opportunity to show FDA that they no longer want to be part of the problem but part of the solution.  I have always subscribed to the notion that “you don’t get if you don’t ask!”

Until next time...

Good Luck and Good Surfing (on the Internet that is)

blog comments powered by Disqus

• Email This
• Print
• Comments
• Trackbacks
• Share Link

For the first time in history, more people are searching the Internet for health information than asking doctors. Web 2.0 and social media tools are allowing people to discover new ways to connect, learn and engage one other in search of healthcare and drug information.

e-Patient Connections 2009 which will be held in Philadelphia, PA on  October 26 and 27 will feature a number of leading authorities on social media and digital health  Some of the featured speakers include Wired Magazine’s Thomas Goetz, Jay
Bernhardt of the CDC, and Lee Aase of the Mayo Clinic. The conference also offers case studies, 1:1 coaching sessions with industry experts and the latest products from digital health companies.

BioJobBlog readers can use the discount code kru500 to save $500 off the current price.

See you there!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

While pharmaceutical and biotechnology companies have been reluctant to use social media, Bio-Rad, Applied BioSystems and other life sciences reagent and instrumentation companies have jumped on the YouTube video train with reckless abandon.

A quick perusal of the molecular biology-related videos on YouTube reveals several scintillating titles like “Do the Double Helix,” “DNA Replication Rap,” and my personal favorite from Bio-Rad, “The PCR Song” (see video below)

Until next time....

Good Luck and Good Watching !!!! 

• Email This
• Print
• Comments
• Trackbacks
• Share Link

NextLevel Pharma has organized several life sciences meetings that may be of interest to BioJobBlog readers. These include: a webinar entitled “Safety Biomarkers in Drug Development” on October 14 and 21, 2009; a conference, “Best Practices in Phase IV Clinical and Observational Research” December 3-4, 2009 in Prague, Czech Republic and “Advancing Biologics from the Lab to the Clinic", January 11-12, 2010 in Brussels, Belgium.

Each of these offerings offers ideas and insights into important issues that are emerging in the life sciences industry. Check it out!

Until next time....

Good Luck and Good Job Hunting!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Mark Senak at the EyeonFDA blog reported yesterday that the US Food and Drug Administration (FDA) is seeking public input on the use of social media in the pharmaceutical, biotechnology and medical devices/diagnostic industry. Meetings to solicit input will be held in Washington DC on November 12 and 13^th.  This will be the first opportunity for industry representatives and the public to begin a discussion with FDA on the policies that will guide the use of social media in the life sciences industry.

According to EyeonFDA, on Monday, the agency will publish a notice in the Federal Register announcing this historic event (see excerpt below)

Questions have arisen regarding the application of the prescription drug and device advertising and labeling provisions, regulations, and policies of promotion on the Internet, especially with regard to the use of emerging technologies such as blogs, microblogs, podcasts, social networks and online communities, video sharing, widgets, and wikis. This section briefly discusses the issues the agency has identified as most frequently raised by regulated companies and other interested parties. It should be noted that although a question may raise a particular issue, that does not necessarily mean that the agency will issue guidance or a regulation on that issue. The agency invites comment at the public hearing on the general concept of Internet promotion, positive or negative; on any aspect of Internet promotion that is of interest to the presenter; and on the topics outlined in the following paragraphs. We are specifically interested in data and research on the use of social media tools in promotion, including data from companies on their own experiences, the extent to which health care professionals and consumers are using and are influenced by various social media tools, and the impact of Internet and social media promotion on the public health.

For the past year or more, many bloggers and other social media enthusiasts have taken FDA to task for not taking action on the topic. Finally, the agency realized that something had to be done given the growing use and popularity of social media tools and strategies in other less regulated industries. Earlier this week, in an unexpected move, FDA launched its first Twitter feed. Perhaps this was a hint that FDA is beginning to emerge from the dark ages into the digital world of Web 2.0 and social media.

Hat tip to Mark!

Until next time...

Good Luck and Good Twittering !!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Mark Senak who runs the EyeonFDA blog reported yesterday that the US Food and Drug Administration (FDA) had launched a Twitter account. As Mark aptly points out, FDA’s unexpected leap into social media is ironic given that the agency has been steadfastly reluctant to craft any guidance whatsoever on the use of Web 2.0  technology or social media by drug and device manufacturers. Maybe, the agency was tired of being overshadowed by the Centers for Disease Control in Atlanta, GA whose rapid adoption and use of social media for public health and related issues has been outstanding. 

For those of you FDA aficionados, FDA can be found on Twitter at @FDA_Drug_Info. Despite its very recent launch, the agency already has over 1,700 followers. Not surprisingly, FDA_Drug_Info is following only six individuals and is largely a one-way informational channel. Maybe somebody ought to tell the agency that social media, most notably Twitter, is suppose to be interactive and conversational? Also, couldn’t FDA staffers come up with a better Twitter handle? I mean the use of underlines to separate words in FDA_Drug_Info is so ......Web 1.0!!!! Finally, most of the information tweeted by the agency has to do with drug approvals, workshop announcements, safety warnings, etc. Maybe somebody also should tell them that most life sciences companies block Twitter and other forms of social media. Nevertheless, based on some recent tweets, it appears that the agency is targeting healthcare providers and consumers as their main audiences.

Despite FDA’s Twitter presence, I wouldn’t expect any Web 2.0 guidance or a drug and device social media policy any time soon. I say this because the agency yet to craft guidance on website design and Google Ads—two very ancient internet tools!!!! Maybe they ought to appoint a social media czar at the agency?

Until next time....

Good Luck and Good Tweeting!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

As an iPhone user, I am constantly amazed at the applications that are developed for it. I recently downloaded a flashlight app that converts my iPhone into a flash light in case of a power outage or finding myself in the dark like I did two summers ago at Moosehead Lake in Maine. Just when I thought iphone apps couldn’t get cooler, I learned about a new app called “Outbreaks By Me.” It was developed by researchers at Children's Hospital Boston in collaboration with the MIT Media Lab, enables users to track and report outbreaks of infectious diseases, such as H1N1 (swine flu), on the ground in real time. The application can be downloaded from iTunes.

According to a press release “the application builds upon the mission and proven capability of HealthMap, an online resource that collects, filters, maps and disseminates information about emerging infectious diseases, and provides a new, contextualized view of a user's specific location – pinpointing outbreaks that have been reported in the vicinity of the user and offering the opportunity to search for additional outbreak information by location or disease.” An additional feature of Outbreaks Near Me is the ability to set alerts that will notify users via text or by e-mail when new outbreaks are reported in their proximity, or if users enter a new area of activity. It also offers an option for users to submit an outbreak report which will allow people in cities and countries around the world to interact with the HealthMap team and participate in the public health surveillance process.

What will iPhone app developers think of next— an app for swine flu vaccination?   Now that would be way cool!

Until next time....

Good Luck and Good Swine Flu Hunting!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

I have previously written several posts on the reluctance of life scientists to use social media and online social networking sites. While I realize that scientists may be somewhat socially challenged, the almost universal disdain for social media is puzzling and troubling to me. More importantly, the reluctance of life scientists to embrace social media flies in the face of some revealing new statistics on social media use by the American lay public.

According to a recent survey by Forrester Research, “half of online adults now belong to social networks like, Facebook and Linked In, a 46 percent growth rate year-over-year.” More importantly, almost a quarter of Americans are content creators who write blogs, upload video or audio or post articles online.” Interestingly, the growth of social media is being driven by adults 35 and older. The survey found that four of five adults of all ages use social media including blogs, social networks and review sites. Finally, most adults visit social networking sites, in way or another at least monthly.

Many scientists who I have talked with (mostly graduate students and postdoctoral fellows) primarily use social media to stay in touch with friends or “hook up” with others after laboratory hours are over. And, other scientists—mostly laboratory heads and principal investigators—view social media as a colossal waste of time. Unfortunately, the scientists who underutilize or shun social media don’t understand its hidden potential to advance scientific research and perhaps more importantly to interact with the lay public to demystify “science.”  In my experience social media has been a powerful way to disseminate information and quickly reach large numbers of people. Isn’t this what science is really about?    

Until next time....

Good Luck and Good Job Hunting!!!!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Mark Sendak, author of the incisive EyeonFDA blog and social media enthusiast, has been keeping a watchful eye (pun intended) on the growing number of pharmaceutical companies that are adding channels and videos to YouTube. 

On his blog today, Mark reviews several new channels developed by Novartis, Johnson and Johnson, Teva, Boehringer Ingelheim and AstraZeneca. While a growing number of pharmaceutical companies continue to add new channels on YouTube, Mark contends that the “success of these channels has varied greatly and several companies have obviously developed the channels without any idea of what they would like to do with them and some of the channels show obvious signs of neglect.”

To learn more about pharma’s incursion on YouTube, read Mark’s post!

Until next time...

Good Luck and Good Video Watching

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Twitter is arguably the hottest new platform to hit the social media scene is the past five  years. Twitter devotees are convinced that anything is possible if the microblogging platform is used correctly. In today’s economy, the most pressing need for many people is finding a job. While Twitter is effective for branding, marketing and occasionally some witty intellectual exchanges, its usefulness for jobseekers has yet to be demonstrated. To that end, there was a recent instructional case study on TwiTip—“5 Methods I Used To Get a Job Through Twitter”— that describes how Twitter can be used to find gainful employment. Although the case study focuses on non-science jobseekers, many of the suggestions and recommendations are relevant to those seeking jobs in the life sciences.

Read and learn!!!

Until next time...

Good Luck and Good Job Hunting!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The whole world is atwitter about Twitter (pun intended). One of the reasons why social media tools like Twitter are so effective is that information can reach very large audiences almost instantaneously.

While there are constitutional guarantees of free speech in the US and elsewhere, there are certain things that are safe to tweet and others that are not. This is especially true if you are corporate employee or a jobseeker looking for a new opportunity. While this ought to be intuitively obvious to most, younger and less well-experienced individuals may not know the “unwritten rules” pertaining to office workplaces and job searching.  To that end, there is a wonderful post on the Resume Bear website(@ResumeBear) that lists 20 things that jobseekers and employees should never say on Twitter.  Although some of the examples and recommendations are comical and funny, getting fired or not getting a job because of something you might have said on Twitter isn’t. 

Until next time....

Good Luck and Good Job Hunting!!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Lisa Roner, blogger and editor for EyeforPharma, recommends a podcast on social media that was created by Dr. Andree Bates, CEO at Eularis, a company that applies analytics to determine the sales impact of specific marketing programs.

Dr. Bates says it is an important area for pharmas to become engaged in social media.  In the podcast, she offers some ideas about how pharma marketers might apply these channels effectively. Also, she offers some tips and hints for intrepid pharma employees who are interested in getting started.

To listen to the podcast click here.

Until next time...

Good Luck and Good Networking!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

BioCrowd co-founder, Vincent Racaniello, and I were chatting the other day with Crowdvine’s Tony Stubblebine (the guy who created the BioCrowd software platform) about the reluctance of scientists to embrace social media. Both Vincent and I, both scientists ourselves, posited that scientists are simply asocial or at the very least not comfortable engaging in social activities whether they be online or IRL. Tony, a self-anointed software geek, wasn’t buying into to our argument and noted that even software geeks are social!

This prompted me to do a little research and I found a blog post written by Nachiket Vartak a blogger and doctoral student at the Max Planck Institute for Molecular Physiology. While the blog post focused mainly on reasons why bioscientists won’t use Twitter, I think that many of his observations can be used to generally describe the chilly relationship between many scientists and social media. Before you read on, I must inform you that I paraphrased and embellished some of Nachiket’s original ideas on the subject. That said, here are some of the reasons why bioscientists may not use social media.

1. The reputation of social networking sites
Many scientists disdain social networks because they believe that social networking sites and microblogging platforms like Twitter are nothing more than places to waste time. Those scientists who use social media usually do it in-between experiments and when planning activities which usually involve copious quantities of alcohol, for after laboratory hours fun. In other words, social media is for fun not for work. Also, many so-called serious scientists contend that “real science discussions” only happen on closed e-mailing lists or forums and not in the “open” on social networking sites.

2. The social activation barrier
According to Nachiket, the stereotype that scientists are asocial is well.....err...true! He asserts that many scientists feel more comfortable focusing on themselves (and their research) rather than interacting with others to learn what they have to say or what they may be thinking. And, many times, unless an individual can demonstrate that they are “smart” they probably aren’t worse listening to anyway. Finally, scientists train for years to become independent investigators. Not surprisingly, there is very little emphasis and importance placed on teamwork or social interactions with others scientists or lay people for that matter. Therefore, it should come as no surprise that many scientists aren’t particularly social or inclined to participate in extracurricular social activities.

3. Privacy aka “secrecy”
Science is a highly competitive endeavor and, in many cases, the discoveries that are made represent many years of sacrifice, blood, sweat and tears. With this in mind, nobody wants to be scooped or beat out by their competitors. Consequently, scientists are generally instructed to be very hush-hush when it comes to sharing any information or data that might give the competition a “leg up” in the competition. Any leak, large or small, could mean the difference between fame and failure and, perhaps more importantly, a successful career as a scientist.

In marked contrast, the success of social media is contingent upon its openness, sharing and transparency. Thus, as Nachiket aptly pointed out social media is antithetical to the very nature of science and scientists.

4. Legitimate channels of communication
The only acceptable and legitimate means of scientific communications are presentations at meetings and publications in peer reviewed journals. These forms of communication are the lifeblood of scientific community and critical to the success of all scientists. If you aren’t published, you have no credibility as a scientist. The scientific publishing and communication industry is big business and “the rules of engagement” in the industry have been well established and institutionalized. Unfortunately, social media threatens to destabilize the science publishing world both financially and philosophically and possibly change the way science information is communicated. Therefore, it should come as no surprise that there is little support for social media in scientific publishing world and the science community in general.

While the number of science blogs and podcasts continue to increase daily, scientific social networking sites continue to struggle. This is because the information flow in blogs and similar forms of social media can be easily monitored and controlled. This is not the case for social networking sites like BioCrowd and microblogging platforms like Twitter.
However, if scientists are truly asocial beings then none of the existing science social networking sites will gain traction and be successful. Call me crazy, but I think social networking is an ideal medium for scientists to exchange information, ideas and develop relationships that can help them jumpstart their careers!

Until next time...

Good Luck and Good Networking!!!!!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

Berci Meskó author of the Science Roll blog recently compiled a list of sites that keep track of the scientists who use Twitter. He recommends: Science Pond (real time), Sciencebase (compilation) and for those of you with a medical bent the Medical Student Blog (compilation). And, for a list of medical journals that are tweeting check out this site. While the lists aren’t comprehensive you might be able to find friends, colleagues and journal editors who use Twitter.

Hat tip to Berci!

Until next time...

Good Luck and Good Tweeting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

During my recent trip to Vermont and Woodstock, NY I had several conversations about Twitter. Surprisingly, I was being asked to explain Twitter to my nephews, both of whom are in their early 20s and to family friends who are in their late 40s and beyond. Also, at several recent science career fairs that I attended many graduate students and postdocs had never heard of Twitter or it they had, they don’t use it. Initially, this was puzzling but after considering the most recent Twitterverse demographics –I think the average age of Twitter users is around 35 to 40—it made more sense to me.

Anyhow, I have found that it is time consuming to explain Twitter to people who have heard about it but don’t quite understand how it works. To that end, several people— who I follow on Twitter— (@ LaurieDesAutels and @Recruiting Animal) tweeted about an article by John C. Dvorak that offers an excellent review of Twitter and several practical ways to use it.

I hope that the article provides some insights into Twitter and how scientists might be able to harness its incredible power and reach. You can follow me on Twitter @biojobblog!

Until next time...

Good Luck and Good Tweeting!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

At the recent Social Communication and Healthcare conference I was invited to run a roundtable discussion entitled “How to Build a Social Networking Site for Bioprofessionals.” The discussions were well attended, primarily by employees several pharmaceutical companies and vendors who sell scientific equipment and reagents. Several bloggers and medical communications professionals also attended.

While microblogging platforms like Twitter are slowly supplanting traditional networking sites as the social medium of choice, themed online communities like BioCrowd--hich was exclusively designed for bioprofessionals ranging from scientists to venture capitalists—are still useful for jobseekers and people who are interested in a “richer” networking experience. For those of you who are interested in social networking sites, I wrote a brief synopsis of the two roundtable discussions that I conducted.

Please feel free to contact me with any additional thoughts, ideas or comments you may have about the piece.

 Until next time...

 Good Luck and Good Networking!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Pharmaceutical,biotechnology and other companies that sell prescription drugs and devices are deathly afraid of adverse events (AEs) associated with their products. For those of you who may not know, companies with approved prescription drugs and medical devices are required to track and report any adverse events associated with their products to regulatory agencies like the US Food and Drug Administration (FDA). If FDA receives enough AE complaints about a product, the agency will investigate to determine whether or not there may be efficacy, safety or tolerability issues with it. And, if FDA thinks that the AEs are legitimate, it may ask a company to conduct Phase IV clinical trials with the product in question or require that changes be made to the product’s label. Not surprisingly, these outcomes can be time consuming and perhaps more importantly, costly. Label changes—especially for blockbuster products—frequently lead to changes in physician prescribing habits which can translate into a loss of revenue. Despite the fact that ALL drugs exhibit AEs, many companies falsely cling to the hope that there will be few, if any, AEs reported for their products.

While drug makers are very familiar with the range of possible AEs associated with their drugs—all AEs for a drug are identified and reported during clinical trials—pharmaceutical executives are concerned about social media activities, because they fear that than the number and frequency of AEs reported for their products will increase. This, in turn, would prompt FDA and other regulatory agencies to investigate and more closely scrutinize their marketed products. As Jonathan Richman, author of the Dose of Digital Blog points out in an excellent post entitled the “Myth of Adverse Event Reporting” AEs are a fact of life for prescription drugs. And, that social media may help to improve adverse reporting. Like Jonathan, I contend that social media might allow drug makers to more effectively identify potential safety issues with a product earlier in its lifecycle and thereby minimize possible deleterious effects of the drug on certain patient populations. I think that drug manufacturers ought to begin to consider how they might effectively use social media to improve AE reporting rather than ignore the potential upside of this new medium.

The Myth of Adverse Event Reporting

Adverse Events are nothing more than negative reviews. If you want people to genuinely talk about your brand, they are going to say negative things. But how often do posts include adverse events? Nielsen decided to take a look at this rather than simply assume it was ” a lot,” which of course is a difficult number to manage. Nielsen looked at Yahoo Health boards and took 500 postings. Of these, only 1 contained enough information to qualify as an adverse event that needed to be reported. That’s 0.2%. Why so low? Turns out that someone simply saying that your drug caused them to have a headache isn’t enough to qualify as an adverse event. Nielsen summed up the pieces of information required to report an adverse event and there are four pieces: “(i) an identifiable patient; (ii) an identifiable reporter; (iii) a specific drug or biologic involved in the event; and (iv) an adverse event or fatal outcome.” (Hat tip to Pharma 2.0 for the summary). The study showed that one or two of these pieces were often available, but not all four. In addition, they found that it would be impossible to get all four even with some effort. In fact, the FDA says, “[Without these pieces] a report on the incident should not be submitted to the FDA because reports without such information make interpretation of their significance difficult, at best, and impossible, in most instances.”

This is because people often don’t register or leave their personal information in a post, so there is no way for a company to follow up and fill in the blanks. Naturally, if there is something significant, every effort should be made, but on the often anonymous Internet, this is usually difficult. Suppose for a moment there were several adverse events that need to be reported. How often do they need to be reported? The FDA is pretty clear on this. For new drugs, reports need to be filed quarterly for three years. After that, it’s annually. For “serious and unexpected” events, these have to be reported within 15 days. However, there’s a pretty high threshold for an adverse event to be considered “serious and unexpected.” Every company already has these reporting channels in place, so it is simply a matter of including adverse events received from social media into the workstream. 

Yes, it’s a balance. The fact is adverse events should not be the reason why healthcare shies away from social media. These risks can easily be mitigated and, if done right, can actually be used in a positive way. So, don’t use adverse events as an excuse anymore. You’ve got the data. 1 in 500 posts include a reportable event. You report quarterly at most (which you’re doing anyway). How much ongoing effort do your other marketing programs require? Probably quite a bit more than this. Next time you hear this excuse, you’ve got the data to dispel the myth of adverse event reporting.

Until next time...

Good Luck and Good Job Hunting!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Mark Senak, author of the EyeonFDA blog and social media enthusiast, posted a great piece about pharma’s reluctance to adopt social media and the changes in adverse event reporting-- aka pharmacovigilance--requirements that may change this attitude. 

Hat tip to Mark!

Until next time...

Good Luck and Good Job Hunting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

I met Jonathan Richman,the author of the Dose of Digital blog, last week at the BDI Conference (#BDI) on Social Communication and Healthcare in NYC. BTW, for those of you who were unable to attend, you missed an informative and compelling meeting on the status of social media in the pharmaceutical and healthcare industries. Anyway back to Jonathan. He gave a great talk on pharma and social media which prompted me to visit his blog. While perusing Dose of Digital, I came upon a wiki that Jonathan maintains called --what else-- the Pharma and Healthcare Social Media Wiki.” 

It’s a comprehensive, cataloged list of social media initiatives underway at pharma, biotech and healthcare industries. Noticeably absent from the wiki, are social networking sites like BioCrowd that were specifically created for life scientists and other bioprofessionals. Hey, wait a minute, aren’t scientists the lifeblood of the life sciences industry? Would there be a life sciences industry without scientists? Hmmmm....I will have to talk to Jonathan about this!

I highly recommend you check out the wiki if you are a life sciences social media enthusiast!

Until next time...

Good Luck and Good Social Media Hunting!!!!!  

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The “Social Media and Healthcare” conference that will be held on July 23, 2009 in NYC at the Graduate Center of The City University of NY (365 Fifth Avenue at 34th Street) is shaping up to be a great one. At present, over 350 people have registered for the meeting. There are a few slots left if you are interested in attending.

Several BioJobBlog readers have asked whether or not the sessions will be recorder and available online. Steve Etzler, one of the conference organizers told me that Blogtalkradio.com will broadcast and archive the audio from all of the case studies that will be presented during the morning sessions. Unfortunately, the round table discussions won’t be available.

As I may have mentioned, Cliff Mintz, Co-Founder of BioCrowd will be leading a roundtable discussion entitled “Building Social Networking Sites for Bioprofessionals.”

See you on Thursday!!!

Until next time....

• Email This
• Print
• Comments
• Trackbacks
• Share Link

BioJobBlog and BioCrowd along with the Business Development Institute, the Journal of Communication in Healthcare and others are co-sponsoring a meeting entitled “Social Media and Healthcare” that will be held on July 23, 2009 in NYC at the Graduate Center of The City University of NY (365 Fifth Avenue at 34th Street). Topics that will be covered include:  

1. Managing regulatory and legal issues when planning and implementing social media strategies
2. Is there a role for social media in President Obama’s healthcare reform plans?
3. Why real-time social media tools like Twitter are gaining momentum and when it makes sense to use them
4. How social media has affected crisis communications in the healthcare industry
   
5. Selling social communications projects and proving ROI to senior management
   
6. Creating and participating in communities to achieve communication, educational and branding objectives
7. Planning and executing a social communications plan with little or no budget
8. Building relationships and partnerships with new healthcare media leaders beyond advertising
9. Best practices for using social communications to connect internally with employees and stakeholders
   
10. Tools, technologies, and best practices for monitoring and measuring social communications

The meeting’s agenda features case study presentations and a series of roundtable discussions on social media topics. I will be leading a roundtable discussion called “How to Build a Social Networking Site for Bioscientists.” Approximately 300 senior marketing, communications and media professionals from Fortune 1000, middle market and emerging growth companies are expected to attend from leading pharmaceuticals, medical technology/device companies, managed care providers, hospitals, healthcare media companies, government and nonprofit organizations.  

BioCrowd members can register for the meeting at a discounted rate of $155. Check it out—it will be money well spent!

Hat tip to Steve Etzler at the BDI and Mario R. Nacinovich Jr., Editor-in-Chief, Journal of Communication in Healthcare for organizing this topical and important meeting.

I hope to see you at the meeting next Thursday!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

Mark Senak, who writes the outstanding Eye on FDA blog, posted an interesting article today that tracks the number of warning letters issued by DDMAC (the center that oversees life sciences marketing and advertising) over the past 12 years. Not surprisingly, the number of warning letters issued by DDMAC fell precipitously during the Bush Administration, after reaching a high during the waning years of Bill Clinton’s presidency. In fact, the number of warning letters issued by DDMAC during the first two quarters of 2009 exceeds the yearly total of warning letters issued in the past 4 of five years. However, as Mark clearly points out, the 2009 year to date number of warning letters may be artificially inflated because of 14 identical ones issued on the same day (April 2) to 14 different companies regarding internet search engine advertising. Nevertheless, it is becoming increasingly apparent that the agency is beginning to emerge from a long slumber and that US regulatory oversight may be entering a new, more scrutinizing era. 

While increasing regulatory scrutiny may be appropriate after 8 years of no regulation at all, it is important that FDA doesn’t overreact and unnecessarily stifle new drug and product development. To that end, I believe that the agency needs to be reorganized, revamped and revitalized to replace its traditionally “reactive” way of doing business with a more “proactive” one.  For example, there is a burgeoning need for regulatory guidance on the use of social media by companies in the pharmaceutical, biotechnology and medical devices and diagnostics industries. Unfortunately, FDA has been unwilling or unable to enunciate a cogent regulatory strategy or any meaningful guidance on this topic. Consequently, many life sciences companies have refrained from using social media because they simply don’t know how to implement it in the current regulatory environment. I believe that FDA, not the companies it regulates, should take the lead on this issue.

Finally, it is becoming increasingly apparent that many companies will continue to refrain from using social media and other Web 2.0 tools until FDA crafts some useful guidance on these topics. Sadly, Web 3.0 is just around the corner and the agency is still struggling with regulatory guidance for corporate websites. Maybe Congress needs to craft some new FDA modernization legislation—it has been 12 years since the last modernization bill was passed!

Until next time....

Good Luck and Good Job Hunting!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

While life sciences companies are still reluctant to take the “social media plunge,” many other companies (with active social media programs) frequently hire employees known as social media managers who oversee and run their social networks.  This is because successful social media websites require daily attention and are extremely time consuming and labor intensive. In general, employees who are hired for these jobs have strong backgrounds in social media and technology but frequently possess little expertise in the industry that they are working in. Because social media is so new, many hiring managers believe that the social media and technology skills of these managers are more important than an understanding of the industry that they work in. However, while this practice may be acceptable in other industries, it won’t be the case for the social media managers who oversee pharmaceutical, biotechnology and medical devices and diagnostics social media websites. These managers will likely be required to have a firm understanding of current rules and regulations guiding drug development and marketing and advertising of approved life sciences products. This will be necessary if the drug makers who hire these managers want to steer clear of regulatory scrutiny by the US Food and Drug Administration and other regulatory agencies.

Based on my experiences as an industrial scientist and more recently as a social media manager, a person with a PhD degree with at least one course in regulatory affairs, good oral and written communication skills and an interest in social media ought to be an ideal candidate for these positions. To that end, those of you who may be interested in this newly, emerging career path option ought to begin training as soon as possible—these jobs will be in high demand at life sciences companies, medical communications agencies and conference organizers in the next year or so!

Until next time....

Good Luck and Good Job Hunting!!!!!!!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

For those of you interested in the Canadian biotechnology scene I want to mention a good resource that I came across recently. The Canadian BioTechnologist 2.0 Blog (http://cbt20.org) has its sights set on helping to advance the development of the Canadian Biotechnology sector and the people who study biotechnology and life sciences at the college and university level and bench scientists and technicians who work in the field across the country.   

Readers are invited to contribute content: posters, tools, research and presentations, articles white papers, multimedia, music downloads and entertainment, conference announcements, videos.

The site is sponsored by the Canadian operation of Bio-Rad so it has a good selection of non-commercial content from the company including papers, tools, workshops and for fun some of their recent music videos. The blog manager, Howard Oliver of What If What Next  a Toronto based  Web 2.0-PR firm has done a great job of collecting content that covers Canadian biotechnology news and useful tools and career information for bench scientists and technicians and students.

Do drop by The Canadian BioTechnologist2.0 Blog (http://cbt20.org) to learn about the Canadian scene and get your voice heard.

 Until next time,

Good Luck and Good Jo

• Email This
• Print
• Comments (3)
• Trackbacks
• Share Link

I just learned from Diego Pineda who runs the Medical Writer Blog and Medical Writing social network about an interesting internship possibility at Science magazine. For those of you social media enthusiasts interested in the opportunity, here is a job description.

“Science, the world's leading journal of original scientific research and global news, seeks a three-month intern to help implement and manage social media projects for its news department. The candidate should be very familiar with Facebook, Twitter, and other social networking platforms, and should have experience creating content for these platforms. Other duties will include promoting news content on the internet, moderating comments on our daily news site, and repurposing news content for multimedia projects. Some writing and research assistance for our online news site is possible. The ideal intern will have a science background-or at least a strong interest in science-and some journalism experience. The internship will be at our Washington, D.C. headquarters.”

For consideration, send a resume and cover letter to AAAS, Human Resources Department, 1200 New York Ave., NW, Suite #101, Washington, DC 20005.  (Attn:  Requisition #1763) You may also reach us by Fax at 202-682-1630 and e-mail at jobs@aaas.org.

It appears that Science is finally getting into the social networking.  For those of you, who can’t wait for the Science network, please check out BioCrowd, a social networking community focused on career development for bioprofessionals.

Until next time....

Good Luck and Good Job Hunting!!!!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The debate, if you can call it that, over whether or not interactive social media platforms like Facebook and Twitter can be used in the life science industry is moving forward at glacial speed. I decided that it was time to propose some ideas rather than continue to admonish the US Food and Drug Administration (FDA) for a lack of guidance.

There are several reasons which may explain the inertia surrounding the adoption of social media by pharmaceutical, biotechnology and medical devices and diagnostics companies. First, and perhaps foremost, FDA has been consistently reluctant to craft any useful guidance on the use of Web 2.0 technologies for research, clinical or promotional purposes. The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) is still trying to figure out how to regulate website content. Is it any wonder that FDA is reluctant to tackle the regulatory implications and issues associated with social media platforms like Facebook and Twitter? Second, a majority of social media advocates— who are leading the charge at many life sciences companies—are marketing and advertising executives who tend to look at social media strictly as a promotional tool. Finally, much of what takes place at life sciences companies is proprietary and confidential—information flow between the company and its employees and the public is fastidiously monitored and tightly regulated. Because of this, the life sciences industry’s “process” is intentionally opaque—which is contrary to the goals of social media which is to promote transparency (or the illusion of it).

There is no doubt that the life sciences industry is the most highly regulated industry on the planet. While this represents a formidable challenge for adoption of social media, it is by no means insurmountable—especially if social media is used for purposes other than branding, marketing and advertising. For example, the most straight forward application of social media at life sciences companies would be in the areas of corporate recruitment and employee retention. Many Fortune 500 companies outside of the life sciences industry have been using Facebook, MySpace and LinkedIn for years for recruiting purposes. While not commonly acknowledged, life sciences companies have quietly begun to use Facebook, LinkedIn and MySpace to recruit prospective employees. Interestingly, the new kid on the block—Twitter—looks to potentially be a more powerful recruiting tool than any of its predecessors. Unfortunately, employee retention is no longer a priority at many companies. However, before the economic meltdown a number of companies, most notably Best Buy, were experimenting with social media to retain talented employees.

Another potential use of social media is for pharmacovigilance and adverse events reporting. Companies with approved products on the market are required by FDA (and other regulatory agencies that approved their products) to set up post marketing surveillance programs for adverse events reporting. By law, companies that receive adverse events reports from consumers, physicians or other entities must report them to the regulatory agencies that approved the product. Regulatory agencies maintain adverse events databases for all approved drugs and devices to monitor drug safety.  If designed and implemented correctly, interactive social media platforms like Facebook and Twitter (which operates in real-time) would make excellent pharmacovigilance and adverse reporting tools. Quite coincidentally, John Mack, who runs the Pharma Marketing Blog, reported a partnership between UCB and PatientsLikeMe.com to create a pharmacovigilance reporting platform for UCB products.

Recruiting patients for participation in clinical trials (to assess efficacy and safety of prospective new drugs) has become extremely challenging over the past few years.Traditional patient recruitment strategies include print, television and radio ads and in some instances, websites. All of these recruitment methods are costly, labor intensive and limited in their effectiveness because they only reach small number of prospective clinical trial participants. I contend that Facebook with over 200 million users, LinkedIn with members in over 140 different countries and Twitter which is growing rapidly would be ideal for clinical trial recruitment and retention purposes. Others have also proposed this idea.

Finally, while the use of social media to promote approved drugs and devices may be difficult because of regulatory constraints, it can be utilized to keep the public informed about prospective new medicines and promote a company’s image or brand. There is no question that the public perception of the pharmaceutical industry has been severely tarnished over the last few years.  The industry’s continued lack of transparency and failure to adequately disclose potential safety risks about some approved products continues perpetuate a negative image. One way to restore public trust and confidence is to use social media to actively engage the public in conversation on wellness, addressing unmet medical needs and prospective new medicines and treatments that are being developed. Also, social media platforms could be employed to showcase community outreach programs and discuss educational initiatives to improve science education and training.

Social media is no longer a new phenomenon or technology. It is a legitimate form of communication which has become an integral part of the Web 2.0 experience. I suspect that the life sciences industry will have to make a decision about social media in the not so distant future—or possibly miss a potentially game-changing business opportunity. And, as Ken Kesey aptly said in Tom Wolfe’s ‘The Electric Kool-Aid Acid Test’—“You’re either on the bus…or off the bus.”

 Until next time...

 Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Comments (4)
• Trackbacks
• Share Link

Mark Sendak, a social media enthusiast and author of the Eye on FDA blog, wrote a great post today about an article he saw in the Washington Post entitled “Drug Firms Jockey for Space Online.”

Mark wrote: “Flock?  Flock?  FLOCK?  The only way you could use the term "flock" in connection with pharmaceutical firms and social media is to say that companies are a scared flock of geese.” He goes on to castigate FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) for a lack of a coherent regulatory framework and guidance for the use of social media in the life sciences industry.

Mark aptly describes DDMAC’s guidance surrounding social media and the pharmaceutical industry this way. “No one knows, and DDMAC apparently makes this stuff up as they go along. That is the kind of Whack-a-Mole game DDMAC plays.  We won't tell you what is off limits, until you do it and then WHACK! Is this anyway to run a pharmaceutical industry?

I am in total agreement with Mark on this issue. Despite the rapid adoption of social media by other industries, FDA has consistently been reluctant to issue any regulatory guidance what so ever on the topic despite assertions to the contrary. Unfortunately, when it comes to social media and the pharmaceutical industry, FDA’s usual approach to regulatory guidance—reactive rather than proactive—is still alive and well. As you may recall FDA previously sent warning letters to no fewer than 14 pharmaceutical and biotechnology companies admonishing them on their placement of product ads on search engine results pages. The fact that 14 different companies received warning letters on this issue reflects the confusion and lack of guidance offered by FDA on social media and the use of Web 2.0 technologies to promote or support the sale pharmaceutical products.

The growing popularity and inevitability of social media suggests that DDMAC officials along with industry representatives must begin to consider crafting a preliminary regulatory framework for its use in the life sciences industry. Like it or not, social media is here to stay!

Hat tip to EyeonFDA!

Until next time....

Good Luck and Good Job Hunting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The advent of social networking sites like MySpace, Facebook and Linked In have been a boon to recruiters and human resources (HR) professionals. Social networks represent a vast and easily-accessible source of job candidates whose professional credentials and personal information are readily available to determine whether or not they may be potential new hires. While the effectiveness of recruiters and HR professionals to source new talent is debatable, I contend that there is nobody more qualified than employees at a company to identify prospective new employees who may bring value to an organization. A number of forward-thinking companies have realized that the best way to find “right fit job candidates” is to mine the social networking contacts of their existing employees. To that end, Appirio and Jobvite, two San Francisco, CA-based start ups, developed software platforms that allow their clients to link employee social networks and candidate sourcing solutions to employee referral programs. 

A hiring company that uses Appirio’s application, ask its employees who belong to Facebook to add the application to their personal pages. When new jobs are available, Appirio’s matching engine searches the Facebook pages of an employee’s friends and uses job titles, geography and key words to determine which friends might be a good fit for the available positions. Once identified, a friend receives a referral from the employee inviting him/her to apply for the job (if interested). If the “friend” is ultimately hired, Appirio’s application allows the company to identify which employee found the match and offer a referral bonus. To address privacy concerns, the list of possible matches is available to only to friends/employees—not the hiring company or Appirio.

Jobvite offers a similar service but in addition to Facebook, it also searches and mines friend/contact information from Linked In and Twitter. And, anyone who receives a Jobvite referral can also search his/her own network to identify suitable job candidates and pass it along again. Jobvite recipients who are hired can be tracked to the original sender, so that the employee can receive a referral bonus—even if the Jobvite referral has been passed from one inbox to another up to six times.

Despite the explosion of job boards, social networking sites and social media tools like Twitter, employee referrals are still the most effective way for jobseekers to find new jobs. The Appirio and Jobvite solutions represent a novel way to leverage employee relationships to match jobseekers with prospective new employers. However, in this job market, I wouldn’t sit around and wait to receive an Appirio or Jobvite invitation from one of your social networking friends. Instead, I recommend that you put your social networking sites to good use and tell everyone you know that you are actively seeking employment.  Because at the end of the day finding a new job is all about networking!

Until next time...

Good luck and Good Job Hunting!!!!!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks (1)
• Share Link

The New York Times reported today that for the first time, Internet users are spending more time on social networking and video sites than on e-mail. According to a report by Nielsen, there was a 1,905 percentage change in the time that users spent viewing online video and an 883 percentage increase in social networking use from February 2003 to 2009.

These changes represent something of a paradigm shift in consumer's relationship with the Internet. People are increasingly moving away from portal-oriented sites, like shopping directories to social networking sites like YouTube and Facebook and providers of niche content.

While marketers have yet to master advertising on social networking sites, Internet pundits and social media enthusiasts believe that over the next year or so a viable business model will emerge that is reliant on social networking user influence and opinions.

Until next time...

Good Luck and Good Networking!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

There has been no shortage of conversation lately about current problems facing the pharmaceutical and biotechnology industries. These industries are faced with the effects of the global recession because of a dangerous combination of falling revenues and spiraling costs. Life sciences company executives are looking for ways to cut production costs and cope with the current decline in drug sales.

“Social networking sites are great to catch-up with old friends, share photographs, music and links but in this climate does the executive community have time for this?” asked Spencer Green CEO of MeettheBoss.com “Credit isn’t the only casualty of the crunch: time is another scarce resource for executives, they need immediate value when online to inform stakeholders and update the public on need developments.

MeettheBoss.com, first launched for the financial services sector in 2008, has just unveiled a new and improved version – redesigned with increased functionality and features, and specifically launched to keep life sciences professionals abreast of late breaking news and trends in the industry. Free Video Roundtables, executive broadcasts and “smartwords” are some of the new functions for the executives to communicate with stakeholders and the public at large. More importantly, it provides instant access to a network of your peers. Also included in the new launch is an upgraded version of MeettheBossTV,an online television channel dedicated to business leaders. The first week of MeettheBoss pharma will feature John Earley, global head of lean and supply at AstraZeneca and Steve Dreamer, VP and head of engineering at Novartis.

While similar to BioCrowd, a social and business networking site for ALL bioprofessionals, MeettheBoss.com is almost exclusively focused on the "goings on" in the pharmaceutical industry.

Please drop me a line and let me know whether or not you like MeettheBoss

Until next time...

Good Luck and Good Networking!!!!!!!!
 

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

Unlike others, life scientists have been slow to use social media to look for jobs or network to enhance career opportunities.  Many scientists  have  Facebook accounts but view it and other social media tools like Twitter simply as a means to stay in touch with family and friends.  However, social media can be a very powerful tool for scientists who are looking for jobs or the next big career move.

To that end, I presented a seminar at Experimental Biology this past weekend in New Orleans entitled "Social Media and Career Development for Life Sciences" that offer suggestions on how to use social media to land a job or jumpstart a career in the life sciences industry.  For those of you who may be interested, I posted the presentation below:

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Twitter, which is currently de rigueur in social media circles, is emerging as one of the most powerful branding and marketing social media tool that has been developed to date.   While other industries are already exploiting Twitter’s powerful marketing reach (to hawk their wares), drug makers have been reluctant to adopt Twitter and most other forms of social media. Industry analysts and company insiders contend that pharma’s reluctance to adopt social media can be attributed to the US Food and Drug Administration’s (FDA) lack of guidance on its use for promotional purposes. At present, it is anybody’s guess when this guidance may be issued, if ever.

Nevertheless, as always, there are a few daring companies willing to “boldly go where no pharma company has gone before”—in this case—Twitter! These companies include Boehringer Ingelheim (BI), Astra Zeneca, Novartis and Pfizer. According to a post on the Advance Market WoRx blog, BI is leading the way among pharma company Twitterers, with 679 following, 745 followers and 47 tweets. AstraZenecaUS has 136 following, 440 followers and 22 tweets. Pfizer has 351 following, 462 followers and 48 tweets.  Novartis has 0 following, 681 followers and 40 tweets (I guess Novartis has a thing” against following people).

Unlike its fellow pharma Twitters, BI—which began using Twitter in November 2008—actually uses it as an interactive and conversational microblogging platform (as it was intended). The other pharma company Twitters use it almost exclusively “as a one-way PR feed” says Ellen Hoenig Carlson at Advance Market WoRx. According to a post on the Pharmafocus website, "Boehringer has incorporated Twitter into its wider communications strategy and is using the site regularly to engage its stakeholders. In addition to posting press releases, BI uses Twitter to recommend web-based information about therapeutic areas and articles that its followers might find interesting or useful. To keep its finger on the pulse of the Twitterverse, BI uses media scanning programs to help monitor online conversations and responds quickly to join in or start up Twitter conversations.”

Kudos to Boehringer for recognizing Twitter’s potential to communicate with patients, physicians and other interested parties. I hope that more pharmaceutical companies begin to use Twitter and other forms of social media to engage and improve communications with their stakeholders.

Until next time...

Good Luck and Good Twittering (or should it be Tweeting?) 

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link

Today's New York Times reported that the US Food and Drug Administration (FDA) issued warning letters and ordered 14 pharmaceutical and biotechnology companies to stop running what it calls misleading ads on internet search pages displayed by search engines like Google. The agency faulted the companies for failing to identify product names (brand) and not listing potential side effects (only benefits) for the drugs. In other words, the ads lacked “fair balance” something that FDA stresses and that all drug makers are very familiar with. 

Drug makers and other interest groups pay search engines like Google to place ads on search result pages after someone types in a related search word. The sidebar ads typically contain a eye-catching headline about a relevant medical condition or product and links to websites promoting certain products. The companies receiving warning letters included: Bayer, Biogen Idec, Boehringer Ingelheim, Cephalon, Eli Lilly, Forrest Laboratories, Genentech, GlaxoSmithKline, Johnson and Johnson, Merck, Novartis, Pfizer, Roche, and Sanofi-Aventis. Not surprisingly, most of the world’s largest and most profitable were guilty of running misleading Internet search engine ads.

Historically, drug companies and FDA have engaged in a cat and mouse approach when it comes to advertising and marketing drug and medical devices and diagnostics. This is because FDA’s existing regulations that guide marketing and advertising practices are relatively lax and it provides drug makers with the opportunity to see how far they can push the agency before “they get caught.” While this practice may have been acceptable for print and television advertising, it may no longer be appropriate for Internet advertising— which potentially has a much broader and larger reach than traditional media because there are not national borders on the Web. Unfortunately, FDA has been slow (reluctant?) to react to digital media and is even more perplexed about social media and the drug industry. Rather than continue to play cat and mouse, I think it would be in the best interest of consumers if FDA and drug makers would sit down and craft new guidance on regulating Internet advertising and marketing practices. It is becoming increasingly apparent that the old rules are no longer sufficient as digital and social media continue to evolve.

Until next time....

Good Luck and Good Job Hunting!!!!!!! 

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

Facebook contends that it has over 175 million members, making it the largest social network in the world! Interestingly, according to an article in today’s New York Times, most US members are “still relatively young.” “Facebook offers advertisers a target of 54.4 million members of all ages. But if an advertiser wants to narrow its target audience to those 25 or older, the number drops to 28.8 million. Narrow it to those 30 or older, and Facebook has 20.3 million to offer.” However, this is not surprisingly because people 30 and over weren’t allowed to join Facebook until 2006. In fact, many over-30 individuals have yet to sign up! In support of this, I am increasingly getting friend requests from my contemporaries—most of whom are in their 40s and 50s.

Each week, a million new members are added in the United States and five million globally—the 30-and-older group is its fastest-growing demographic (and the one with the most money to spend).  Further, Facebook members are becoming increasingly social and gregarious. In December the average number of “friends” per member was 100. Since then, it has grown to 120 per member according to a Facebook spokesperson. If Facebook continues to grow at its current rate, it will likely experience unprecedented and astonishing growth in the next few years. And, when it comes to monetizing social networks, bigger is always better!

Until next time...

Good Luck and Good Networking!!!!!!!!!! 

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Social media is the rage these days and, by all accounts, the things that are driving it popularity are making business connections, job hunting and the opportunity to meet/connect with others on a personal/romantic level. While scientists are generally perceived as being less social than others, I believe that we, like most people, primarily join social networks for two reasons—job hunting and career development or dating and sex.

With this in mind, a quick perusal of social media sites reveals that there is no shortage of social networks specifically designed for scientists for job hunting and career development. Surprisingly, there is a dearth of sites that enable scientists to connect with one another on personal or romantic levels. This doesn’t make sense to me as someone who spent 12 years as a graduate student and postdoc. Let’s face it, we scientists generally work long hours, don’t get out of the laboratory much and generally find it hard to meet prospective mates. That is, outside of the people who we work with daily. And as I learned the hard way, workplace romances can be very tricky and uncomfortable to manage at times. But, not to worry! Yesterday, I discovered an interesting website called Science Connection—maintained and run by the Scientist.com—which was specifically designed as a “the meeting place for single science professionals and others with an interest in science or nature.” I guess you can call it match.com for scientists!

From what I could glean from its website, Science Connection was started way back in the early 1990s by “erstwhile biologist Anne Lambert, with help and advice from friends who were also biologists, birders, or science types, and with the essential involvement of her friend Roy Smith, who did the original programming.” The site boasts about 15,533 members and provides some cool stats on the number of matches, relationships, marriages and even children that resulted from members who joined the network. Most of SciCon’s members are from the United States and Canada, with small numbers from other countries and regions of the world. The scientific disciplines of its members run the gamut from physical, natural, medical and social/behavioral sciences to computers and information technology. And, some of SciCon’s members aren’t scientists but lawyers, teachers, business people, musicians and artists (science fetish?).

But, before you take the SciCon plunge, you ought to know that the average age of male members is about 49 years and for women almost 46 years. However, those averages are misleading because they were calculated from the roughly 500 members who listed their ages on their profiles. There are roughly equal numbers of men and women and the age of its members ranges from 20 to 89 years. Many members are into natural history (birding, etc.) and participate in outdoor activities.  Finally, SciCon is not a free site and annual membership is $65 (~ 18 cents/day). “The $65 annual fee buys you a list of all members of the opposite sex (what about same sex individuals?) and a monthly newsletter, which has mini-profiles, discussion forums and a place where members can announce get-togethers in their area. Member Polylogue includes in-depth analyses of cyber romance, the perils of over-50 dating and friendships that bud into romance. If the $65 annual fee is too steep a price to pay for love, then you might want to consider a three month membership which costs only $30 (~33 cents/day). However, as stated on the website, the $65 annual membership represents the “the best value.”

While I had never heard of the Science Connection before, the network has been reviewed many times in the past by a variety of media outlets that include: NPR, Newsweek (2006), Discover (2007), Forbes Magazine and others. In general, the site gets favorable reviews. That said, if I wasn’t married (my wife is lawyer) I might consider joining Science Connection. After all, it certainly beats sitting around the lab on Friday and Saturday nights analyzing sequence data—not that there is anything wrong with that!

Until next time...

Good Luck—and well, err—Good Luck

• Email This
• Print
• Comments
• Trackbacks
• Share Link

I have been accumulating anecdotal information about companies,organizations and institutions that use social media tools like Facebook, Twitter YouTube etc.  I decided to attempt to conduct an informal survey  to determine whether or not the life sciences sector is adopting and embracing social media to meet its objectives (whatever they may be). 

To that end, I constructed a Google Docs spread sheet to collect information for the survey.  Please take a look at the survey and fill in the requested information. I will publish the results of the survey if enough people response to this request.

I look forward to hearing from as many of you as possible. Don't be shy, everything is anonymous!

Until next time...

Good Luck and Good Tweeting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

After having looked at pharma’s use of twitter, I decided to also get a feel for how pharma is engaging with facebook so far. Three main uses emerge: 1. connecting employees, 2. attracting talent and 3. promoting disease awareness or treatment adherence

1. Connecting current and ex- employees definately has the most activity. Numerous official and unofficial  groups or fan pages bring together the employees of most of the top pharma companies. For the purpose of this analysis let me concentrate the largest groups with apparent corporate endorsement (ie. use of official logo, links to company website and corporate messaging in group purpose).

Sanofi-Aventis, Novartis, Boehringer Ingelheim, Pfizer/Wyeth and Roche seem to be leading the pack in terms of activity. Sanofi and Novartis both set up official fan pages with over one thousand members. Lots of employee activism as well at  Boehringer Ingelheim, Roche, Novartis and Wyeth with facebook groups of 500+ members. (Check out this video from the official BI facebook group, just for fun).

Other, not so active groups: AstraZeneca (also have an English and French fan page), Teva, GSK (French fan page), Lilly, JNJ, and Pfizer.

Interestingly, there are a number of unofficial “Pfizer“ groups expressing negative sentiment towards the company (most of it coming from layed off employees). Pfizer is also the only company that someone set up a group about them, called “conversations of Pfizer“. Not much activity unfortunately, but intersting concept nevertheless.

Another strange aside: Egytian and Turkish country groups seem to exist for basically every pharma company I researched, must be a cultural thing?

2. Regarding attracting talent, there is an overwhelming number of student, intern and training program groups for all companies; most of them probably not official. GSK seems to have the largest number of student groups, a lot of them private. Merck also stands out for its excellent Merck Careers fan page, well done, I think, but not much activity, yet.

3. Promoting disesase awareness is where I believe things finally get interesting for patients. Examples of pharma companies using facebook to drive disease awareness and treatment adherence aare not bountiful, but I did find two great examples.

The first example is the ADHD Moms group, sponsored by McNeil Pediatrics, a JNJ company. The group counts close to 8000 members, but, for me, it is not these numbers that make the group exciting. By setting up this fan page, McNeil has done a great job at creating an environment in which patients/caregivers can receive valuable information concerning treatment management and adherence, while staying within the pharma “comfort zone“.

The concept is simple. One Pediatrician and three ADHD moms, as well as “guest writers“ discuss topics of importance to raising a child with ADHD. There are polls to each topic to get the audience’s feedback, while avoiding  thorny legal issues such as adverse event reporting or off-label usage. The site also offers a podcast series and links to prominent ADHD organizaions.

The second example comes from Novartis Zometa product. It is called: Marica Strassman Takes Role as Patient Advocate. In this group, celebrity and breast cancer survivor Marcia Strassman takes on the mission to “inform breast cancer patients and caregivers about the importance of following treatment regiments outlined by their doctors “. Thus a clear focus on promoting disease awareness and treatment adherence.

The setup up is also highly transparant, clearly disclosing Zometa sponsorship with links to the Zometa homepage, product information and the facebook groupe mission:“ To educate patients with advanced breast cancer and other metastatic cancers about the risks and benefits of Zometa.“

This fan page, like the ADHD example, features links to the most prominent cancer organizations as a further resources for patients. Also, similar to the ADHD page, this site does not allow any comments from its members to prevent any legal issues.

So overall, highly encouraging signs that pharma is starting to use facebook. Most companies still seem to first experiment with more internally focused groups, but some are starting to “test the waters“ and to engage with patients on important topics like disease awareness and treatment adherence.

Silja Chouquet is the owner and CEO of whydot GmbH, an agency specialized in social media consulting, coaching and training. Her fields of expertise are the creation of patient-focused social media communications and marketing campaigns. She runs the whydotpharma blog where she discusses social media and the life sciences and other pharma-related topics.

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Twitter, the microblogging platform, is the current rage in social media. According to @Shwen, who writes the Med 2.0 Blog, it grew by 752% in 2008. Shwen is a social media enthusiast who is trying to convince the life sciences industry that Twitter and other social networks can be leveraged to improve drug development and deliver healthcare.

According to a recent post on Med. 2.0, there are currently three pharmaceutical companies that are actively using Twitter: Novartis (@novartis), Boehringer Ingelheim (@Boehringer) and Astra Zeneca (AstraZenecaUS). Also, it appears that Johnson and Johnson (@JNJcomm) launched an account last week. Tweets from @novartis and @Boehringer occur fairly regularly whereas AstraZenecaUS tweets are rare. Unlike YouTube, where pharmaceutical sponsors who create channels can regulate and control content, it is much more difficult to manage Twitter because tweets are in real time, uncensored (for the most part) and can be globally disseminated within seconds.

Despite these issues, Med 2.0’s Shwen muses “I can only imagine that more pharma companies are going to be jumping on board the Twitter-train sooner rather than later. How they use it to engage, on the other hand, is going to vary greatly from company to company. At the very least, I see companies setting up accounts as “listening posts”, but others may choose to engage, like @boehringer does in an informal manner. Whatever the case, Twitter is fast becoming the new dominant space for listening and/or engaging the life sciences community.”

Like Shwen, I believe that it a matter of time before pharma and biotech realize that they must embrace social media (in all of its various forms) to remain competitive in today’s increasingly interconnected marketplace.

For those of you who may be interested, you can follow BioJobBlog (@Biojobblog) and Biocrowd (@Biocrowd) on Twitter too!

Until next time…

Good Luck and Good Twittering

• Email This
• Print
• Comments
• Trackbacks (1)
• Share Link

We recently added a feature to BioCrowd called BioCrunch. Our goal for BioCrunch is to provide Bcrowd members with relevant, interesting and “fresh” content. Vincent and I are big fans of podcasts and PowerPoint presentations! That said, please contact me  if you are interested in contributing content for BioCrowd’s BioCrunch feature.

Until next time…

Good Luck and Good Surfing!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

 As many of you know, we launched BioCrowd about six weeks ago. Our membership is steadily growing and several early members suggested changes and improvements to the site. In typical Web 2.0 fashion, we listened to those suggested and decided to add several new features!

First, we added a new section to the home page called BioCrunch. BioCrunch will feature “fresh content” developed by BioCrowd members. Items that can be posted to BioCrunch include but are not limited to podcasts, PowerPoint presentations, manuscripts and possibly poster presentations. With this in mind, we urge interested BioCrowd members to send us stuff that you wanted featured in BioCrunch and shared with the rest of the community.

Second, you can now upload multiple files with discussion posts and add a single file to comments. Also, it is now possible to preview your comment or discussion posts (before you hit the send button) to insure that they are grammatically-correct and typo-free. 

Third and perhaps most importantly, we decided to publicly open the site so that RSS feeds from BioCrowd can be imported to other social media applications including blogs, Facebook and Twitter. It also means that member profiles and discussion posts are searchable by Google. However, all posted resumes and job listings will remain private and only available to BioCrowd members, i.e. you have to join to view them.

We are planning other improvements to BioCrowd—stay tuned for new updates!

Until next time….

Join Us and Be Part of the Crowd!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

The Eye on FDA blog reported today that AstraZeneca and Sanofi-Aventis have joined the ranks of Abbott, GSK, J&J and SanofiPasteur on YouTube. Pharmaceutical companies are taking advantage of the power of YouTube and other social media sites because regulatory guidance hasn’t been issued on its use to promote products or brand awareness. In other words, this is uncharted territory and companies can essentially 'test the waters' to see how far regulatory agencies will let them go.  I suspect that early life sciences company adopters of social media will garner substantial ROI before regulatory guidance is issued.

A lack of regulatory oversight, the ability to manage and control content and the low costs associated with creating Internet videos make YouTube and other social media sites attractive to pharmaceutical and biotechnology companies. The life sciences sector is just beginning to recognize the power of social media and the role that it may play in promoting products and brand awareness to consumers.  Expect many more life sciences companies to experiment with social media in the near future--its a veritable goldmine!

Until next time…

Good Luck and Good Video Watching!!!!!!! 

• Email This
• Print
• Comments
• Trackbacks
• Share Link

For those of us who grow up in the New York Metropolitan area, the WPIX Yule was a family Christmas tradition (even for Jewish kids like me). Every Christmas morning, we would get up, turn on the TV, surf over to WPIX and watch the yule log burn all day long. I think that back iin the day, the television station probably ran a video loop (rather than train a camera all day on the yule log) but it was as close as we could come to today's web cams (for reference purposes, IBM mainframes were de riguer at the time). Those were the days!!!!!

Unfortunately, the yule log disappeared for over 30 years until WPIX decided to resurrect it several years ago because of popular demand (there are a lot of baby boomers out there). While many of you don't receive the WPIX digital signal, it doesn't mean that you can't enjoy the Yule log experience. You can now view it on YouTube!

 Happy Holidays!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Do you ever wonder how popular twitter is or how many followers the average twitter has? Well wonder no more. You can find answers to these questions and more by reading ‘State of the Twittersphere (Hubspot Edition)’ that was recently posted on Tech Crunch.

I started tweeting in earnest about two months ago and I am convinced that Twitter and other microblogging platforms are the next generation of social media tools. So, move over LinkedIn, Facebook and My Space because the Twitterverse is expanding.

BTW, you can follow BioJobBlog on twitter @ BioJobBlog.

Until next time…

Good Luck and Good Tweeting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link